Cullinan Associates Inc. Sells 11,400 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Cullinan Associates Inc. trimmed its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 15.3% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 63,200 shares of the company’s stock after selling 11,400 shares during the period. Cullinan Associates Inc.’s holdings in Hims & Hers Health were worth $1,164,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Hims & Hers Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after acquiring an additional 136,907 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after acquiring an additional 3,205,108 shares in the last quarter. Farallon Capital Management LLC raised its holdings in shares of Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after acquiring an additional 1,634,000 shares during the period. Bank of New York Mellon Corp lifted its position in Hims & Hers Health by 67.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock valued at $13,701,000 after acquiring an additional 273,473 shares in the last quarter. Finally, M&G Plc acquired a new position in Hims & Hers Health in the 1st quarter worth $8,232,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Price Performance

Shares of HIMS stock traded up $0.22 during trading hours on Friday, reaching $21.74. The company had a trading volume of 384,120 shares, compared to its average volume of 8,168,936. The business has a fifty day simple moving average of $17.47 and a 200-day simple moving average of $17.78. Hims & Hers Health, Inc. has a 12 month low of $5.65 and a 12 month high of $25.74. The company has a market cap of $4.67 billion, a price-to-earnings ratio of 269.03 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business’s revenue for the quarter was up 51.8% on a year-over-year basis. During the same period last year, the business posted ($0.03) earnings per share. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $487,789.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Hims & Hers Health news, insider Soleil Boughton sold 2,334 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $17.30, for a total value of $40,378.20. Following the transaction, the insider now directly owns 164,475 shares of the company’s stock, valued at $2,845,417.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at $487,789.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 841,076 shares of company stock worth $14,759,219 over the last quarter. 17.71% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Jefferies Financial Group boosted their price target on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Bank of America lifted their target price on shares of Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday. Truist Financial increased their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Finally, TD Cowen upped their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.21.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.